<DOC>
	<DOCNO>NCT00003927</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Amifostine may protect normal cell side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy , amifostine , peripheral stem cell transplantation treat patient stage II , stage III , stage IV breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Amifostine , Peripheral Stem Cell Transplantation Treating Patients With Stage II , Stage III , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate feasibility high dose doxorubicin , cyclophosphamide , paclitaxel , amifostine patient high risk stage II/III responsive stage IV advance breast cancer . II . Determine pharmacokinetic profile paclitaxel administer amifostine regimen patient . III . Assess toxicity treatment regimen patient population . OUTLINE : Patients receive filgrastim ( G-CSF ) subcutaneously twice daily day 1-4 peripheral blood stem cell ( PBSC ) mobilization continue day 5-10 PBSC collection . At least 2 week follow mobilization , patient receive doxorubicin IV continuous infusion day -9 -5 follow cyclophosphamide IV 2 hour day -5 amifostine IV 15 minute , paclitaxel IV 24 hour day -4 . On day -2 , 25 % PBSC reinfused 75 % reinfused day 0 , follow daily G-CSF subcutaneously IV begin day 1 . Patients follow every 3 month 2 year , periodically thereafter . PROJECTED ACCRUAL : A total 15 patient accrue study within 6-8 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven breast cancer include : Stage IV metastatic disease current partial complete response prior induction chemotherapy High risk primary disease le 60 % chance progression free survival 3 year Stage II tumor 10 axillary node involvement Stage IIIA IIIB tumors No bone marrow metastases No CNS metastases No 10 bone metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 59 Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Neutrophil count great 2,000/mm3 Platelet count great 150,000/mm3 Hemoglobin great 9 g/dL ( blood transfusion allow ) Hepatic : Bilirubin great 1.2 mg/dL SGOT SGPT less 1.5 time upper limit normal Renal : Creatinine great 1.2 mg/dL Creatinine clearance least 80 mL/min No prior hemorrhagic cystitis Cardiovascular : Ejection fraction least 55 % MUGA No prior valvular heart disease arrhythmia Pulmonary : DLCO least 60 % low limit predict pCO2 great 43 mmHg room air pO2 great 85 mmHg room air FEV 1 least 2 liter Other : No prior malignancy except basal squamous cell skin cancer , carcinoma situ stage I carcinoma cervix Not pregnant HIV negative Hepatitis B negative No prior history disable psychosocial disorder No CNS dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No 2 prior chemotherapy regimens metastatic disease Prior total doxorubicin dose great 180 mg/m2 Prior total paclitaxel dose great 750 mg/m2 Endocrine therapy : At least 4 week since prior hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy leave chest wall No prior radiotherapy great 20 % bone marrow ( exclude syngeneic transplantation candidate ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>